HOUSTON, March 9, 2021 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage
pharmaceutical company with a broad portfolio of drug candidates
targeting highly resistant tumors and viruses, today announced that
members of management will be presenting at four upcoming
healthcare conferences.
Event:
|
H.C. Wainwright
Global Life Sciences Conference
|
Format:
|
Presentation &
1x1 Meetings
|
Presentation:
|
Presentation will be
available on-demand beginning on Tuesday, March 9, 2021
|
Location:
|
Webcast
Link
|
|
|
Event:
|
33rd Annual Virtual
ROTH Conference
|
Format:
|
Panel, Presentation
& 1x1 Meetings
|
Date:
|
March 15 – 17,
2021
|
Presentation:
|
Presentation will be
available on-demand beginning on Monday, March 15, 2021 at 9:00am
ET
|
Location:
|
Webcast
Link
|
Panel
Discussion:
|
Cancer –
Heterogeneous Approaches to a Heterogeneous Etiology
|
Panel
Date:
|
Monday, March 15,
2021
|
Panel
Time:
|
10am – 11am
ET
|
Panel
Location:
|
Interested parties
may register for the panel here
|
|
|
Event:
|
Oppenheimer 31st
Annual Healthcare Conference
|
Format:
|
Presentation &
1x1 Meetings
|
Date:
|
Wednesday, March 17,
2021
|
Time:
|
8:00am – 8:30am
ET
|
Location:
|
Webcast
Link
|
|
|
Event:
|
Maxim 2021 Emerging
Growth Virtual Conference
|
Format:
|
Presentation
|
Date:
|
Wednesday, March 17 –
18, 2021
|
Presentation:
|
Presentation will be
available on-demand beginning on Wednesday, March 17, 2021 at
9:00am ET
|
Location:
|
Investors can
register for the conference here
|
Audio webcasts of Moleculin's presentations will be available on
the investor relations section of Moleculin's website at
https://ir.moleculin.com/. Replays of the webcasts will be
available for 90 days after the date of the presentation.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors and
viruses. The Company's clinical stage drugs are: Annamycin, a Next
Generation Anthracycline, designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, WP1066, an Immune/Transcription
Modulator capable of inhibiting p-STAT3 and other oncogenic
transcription factors while also stimulating a natural immune
response, targeting brain tumors, pancreatic cancer and hematologic
malignancies, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in preclinical development of additional drug candidates, including
other Immune/Transcription Modulators, as well as WP1122 and
related compounds capable of Metabolism/Glycosylation
Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Contacts
James Salierno
/ Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
jsalierno@theruthgroup.com
cruth@theruthgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-to-participate-in-four-upcoming-healthcare-conferences-301243090.html
SOURCE Moleculin Biotech, Inc.